FindTrial
Sign In

Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19)

Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151227025726N12
Enrollment
20
Registered
2020-03-23
Start date
2020-03-03
Completion date
Unknown
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia. Coronavirus infection, unspecified

Interventions

Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Laboratory confirmed COVID-19 with RT-PCR Respiratory rate > 30/min Oxygen saturation < 90% PaO2/FiO2 < 300mmHg

Exclusion criteria

Exclusion criteria: Chronic kidney Disease Pregnancy or breastfeeding Drug allergy history Pneumonia due to influenza virus, bacterial pneumonia, fungal pneumonia, and noninfectious causes Chronic liver disease Acute kidney injury

Design outcomes

Primary

MeasureTime frame
Clinical response to therapy. Timepoint: Daily. Method of measurement: Clinical symptoms.—

Secondary

MeasureTime frame
Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily. Method of measurement: Observation.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Dastan

Shahid Beheshti University of Medical Sciences

f_dastan@sbmu.ac.ir+98 21 2610 9490

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 27, 2026